Владислав Уткин
在CNP类似物赛道，Ascendis的TransCon-CNP率先实现了剂型升级。与Vosoritide不一样的设计是TransCon-CNP被一层保护分子包裹，降低了体内清除影响，延长作用时间，实现每周一次给药。非头对头临床数据显示，TransCon-CNP每年2.29厘米的增高表现也优于Vosoritide。，详情可参考Line官方版本下载
But she added: "We have been clear that we cannot go further on pay this year, but there is shared ambition to explore and address some of the unique additional costs that resident doctors incur through their training and work."，更多细节参见夫子
力量从思想中汲取，党的创新理论成果引领新的实践。。Line官方版本下载是该领域的重要参考